Lisa Jean Kremer

Lisa Jean Kremer

Auto-generated profile, based on publicly available information

Lisa Jean Kremer

He Rau Kawakawa (School of Pharmacy) Ōtākou Whakaihu Waka (University of Otago) Dunedin New Zealand

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
9 May 2019 in BMJ Paediatrics Open
Verified
Journal Article
Open access
PDF file
LKLisa Jean Kremer
Lisa Jean Kremer
DRDavid M Reith
David M Reith
NMNatalie Medlicott
Natalie Medlicott
RBRoland Broadbent
Roland Broadbent
Introduction Routine retinopathy of prematurity eye examinations are an important part of neonatal care, and mydriatic medicines are essential in dilating the pupil for the eye examination. There are concerns about the level of evidence for efficacy and safety of these mydriatic medicines. Objective This review evaluates both efficacy and safety evidence of mydriatics used during the retinopathy of prematurity eye examination. Method Systematic literature review. Results There is limited evidence guiding clinical practice for safety and efficacy of mydriatics. The majority of publications are underpowered and with an unclear to high level of bias. There are a wide variety of mydriatic regimens evaluated for efficacy and safety, and multiple regimens are associated with case reports. Conclusions Current international guideline seems unnecessarily high, especially when the reviewed literature suggest that lower doses are effective, albiet from underpowered studies. The lowest effective combination regimen appears to be phenylephrine 1% and cyclopentolate 0.2% (1 drop). Microdrop administration of this regimen would further increase the safety profile, however, efficacy needs to be assessed.

27 January 2024 in International Journal for Equity in Health
Verified
Journal Article
Open access
PDF file
PGPapillon Gustafson
Papillon Gustafson
MLMichelle Lambert
Michelle Lambert
KBKaren Bartholomew
Karen Bartholomew
MRMihi Ratima
Mihi Ratima
YAYasmin Abdul Aziz
Yasmin Abdul Aziz
SCSue Crengle
Sue Crengle
Background: Health intervention implementation in Aotearoa New Zealand (NZ), as in many countries globally, usually varies by ethnicity. Māori (the Indigenous peoples of Aotearoa) and Pacific peoples are less likely to receive interventions than other ethnic groups, despite experiencing persistent health inequities. This study aimed to develop an equity-focused implementation framework, appropriate for the Aotearoa NZ context, to support the planning and delivery of equitable implementation pathways for health interventions, with the intention of achieving equitable outcomes for Māori, as well as people originating from the Pacific Islands. Methods: A scoping review of the literature to identify existing equity-focused implementation theories, models and frameworks was undertaken. One of these, the Equity-based framework for Implementation Research (EquIR), was selected for adaptation. The adaptation process was undertaken in collaboration with the project’s Māori and consumer advisory groups and informed by the expertise of local health equity researchers and stakeholders, as well as the international implementation science literature. Results: The adapted framework’s foundation is the principles of Te Tiriti o Waitangi (the written agreement between Māori rangatira (chiefs) and the British Crown), and its focus is whānau (extended family)-centred implementation that meets the health and wellbeing aspirations, priorities and needs of whānau. The implementation pathway comprises four main steps: implementation planning, pathway design, monitoring, and outcomes and evaluation, all with an equity focus. The pathway is underpinned by the core constructs of equitable implementation in Aotearoa NZ: collaborative design, anti-racism, Māori and priority population expertise, cultural safety and values-based. Additionally, the contextual factors impacting implementation, i.e. the social, economic, commercial and political determinants of health, are included. Conclusions: The framework presented in this study is the first equity-focused process-type implementation framework to be adapted for the Aotearoa NZ context. This framework is intended to support and facilitate equity-focused implementation research and health intervention implementation by mainstream health services.

13 October 2020 in Archives of Disease in Childhood
Verified
Journal Article
Closed access
PDF file
LKLisa Jean Kremer
Lisa Jean Kremer
RBRoland Broadbent
Roland Broadbent
NMNatalie Medlicott
Natalie Medlicott
MSMary Jane Sime
Mary Jane Sime
FMFrances McCaffrey
Frances McCaffrey
DRDavid M Reith
David M Reith
Aims To determine if Very low dose mydriatic eye microdrop regimen sufficiently dilates the pupil (above 4.1 mm) compared with the currently used low dose mydriatic eye microdrop regimen. Cardiovascular, gastrointestinal and respiratory adverse effects occur following eye drop instillation. Methods Seventeen premature infants were recruited into this prospective, randomised controlled pilot trial in January 2017 to November 2018. Data were collected from the single-centre Neonatal Intensive Care Unit, Dunedin Hospital, New Zealand. The inclusion criteria were birth weight less than 1500 g or gestational age less than 31 weeks, or any premature infant requiring red reflex testing. Infants were randomised to receive either phenylephrine 1% or 0.5% and cyclopentolate 0.2% or 0.1%, 1 microdrop in both eyes. Efficacy outcome measures were pupil size at retinopathy of prematurity eye examination (ROPEE) and ophthalmologist rating of ease of screen. Results All participants had sufficient pupillary dilation for a successful ROPEE. Ophthalmologists rated the ROPEE as easy for 90% of all examinations. Pupil dilation measurements at the time of examination, mean±SD, 4.8±0.2 (95% CI 4.5 to 5.2) mm for treatment A and 5±0.2 (95%CI 4.6 to 5.4) mm for treatment B (p=0.61). There were no statistically significant differences between the groups for safety data. Conclusions Very low dose microdrop administration of phenylephrine and cyclopentolate appears to be effective at sufficiently dilating the neonatal pupil for ROPEEs. Low dose and very low dose microdrop mydriatic regimens may also reduce the risk of unwanted adverse effects associated with these medicines. Trial registration number Australian New Zealand Clinical Trials Registry (reference ACTRN12616001266459p).

1 January 2021 in Pharmacy Education
Verified
Journal Article
Closed access
PDF file
LKLisa J. Kremer
Lisa J. Kremer
ANAngela Lan Anh Nguyen
Angela Lan Anh Nguyen
TWTe Awanui Waaka
Te Awanui Waaka
JTJaime Tutbury
Jaime Tutbury
KWKyle Wilby
Kyle Wilby
ASAlesha Smith
Alesha Smith
Background: There is increasing awareness of diversity and inclusion needs within health and education systems to help address access and equity issues for minority groups. Although these calls are well known, there is little guidance for those working within these systems to create meaningful change. The purpose of this study was to critically review case-based teaching material within the authors' programmes through the lens of equity, diversity, and inclusion. Methods: A document analysis of clinical workshop cases extracted from all integrated therapeutics courses administered in 2020 was conducted. Results: Sex, age, and employment status were most commonly presented in cases (84.0%, 97.1%, 49.0% respectively). The majority (90.0%) of cases did not have ethnicity defined. The overwhelming majority of cases did not have living situation (68.3%) or sexual orientation (78.0%) defined. Conclusion: Case-based teaching material within a pharmacy programme was largely undefined according to patient demographics and diversity markers. Findings support the notion that teaching material may have a contributory role towards systemic racism, prejudice, and implicit bias.

18 July 2025 in First Nations Health and Wellbeing - The Lowitja Journal
Verified
Journal Article
Open access
LKLisa Kremer
Lisa Kremer
SCSue Crengle
Sue Crengle
KBKaren Bartholomew
Karen Bartholomew
TKTahu Kukutai
Tahu Kukutai

30 March 2021 in American Journal of Perinatology
Verified
Journal Article
Closed access
PDF file
LKLisa Kremer
Lisa Kremer
DRDavid Reith
David Reith
NMNatalie J. Medlicott
Natalie J. Medlicott
MSMary J. Sime
Mary J. Sime
LELiza Edmonds
Liza Edmonds
RBRoland Broadbent
Roland Broadbent
Objective This study was aimed to determine mydriatic regimen(s) used in neonatal units in Aotearoa, New Zealand (NZ), and Australia and to estimate the frequency of adverse drug events following mydriatic administration in preterm neonates. Study Design A cross-sectional survey was sent to neonatal nursing staff listed in the Australian and New Zealand Neonatal Network contact list. Participants were asked to state what mydriatic regimen they use, and to estimate the frequency of adverse drug events when eye drops were administered for retinopathy of prematurity eye examinations (ROPEE). Results Thirteen different mydriatic regimens were identified; phenylephrine 2.5% and cyclopentolate 0.5% (1 standard drop of each) was the most commonly used regimen. Two of the regimens exceeded adult doses and five regimens included a mydriatic that is equivalent to an adult dose. Following mydriatic instillation, the three most common adverse effects were apnea, tachycardia, and periorbital pallor. Conclusion Low-concentration single-microdrop regimens are currently in use and resulting in successful ROPEE, yet doses exceeding adult doses are in use throughout Aotearoa, NZ, and Australian units. We know from this dataset that neonates are experiencing unwanted and potentially preventable, adverse effects associated with mydriatics, and every effort should be made to minimize this risk. Key Points